Presentation is loading. Please wait.

Presentation is loading. Please wait.

Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.

Published byGlenna Darmali Modified over 5 years ago

Similar presentations

Presentation on theme: "Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline."— Presentation transcript:

1 Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients.
Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Baseline is defined as the last non-missing value before the first dose of tomuzotuximab. Only patients with valid baseline and postbaseline values are included. Tumour assessment was not performed in six patients because of early withdrawal from the study following clinical deterioration or AE; two patients had no measurable disease according to RECIST1.1 criteria. The dotted lines indicate the cut-off for partial response (−30%) and progressive disease (+20%). *Patients with stable target lesions but progression because of new lesions. †Patient (CRC, dose 1370 mg) had a best change from baseline of 32.2%, unconfirmed 50 days later (change from baseline 29.5%). ¶ Patient  is still in complete remission (4.5 years) and received tomuzotuximab for 5.2 years. CRC, colorectal cancer; GCA, gastric cancer; NSCLC, non-small cell lung cancer; OVCA, ovarian cancer; PanC, pancreatic cancer; RCC, renal cell cancer; SLD, sum of longest diameters. Walter Fiedler et al. ESMO Open 2018;3:e000303 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline."

Similar presentations

RECIST Overview.

RECIST Overview.
Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.

Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.
Figure 2 Response after initial increase in total tumour burden

Figure 2 Response after initial increase in total tumour burden
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
Volume 65, Issue 4, Pages (April 2014)

Volume 65, Issue 4, Pages (April 2014)
Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
Clinical algorithm of diagnosis and treatment of bone metastasis guideline. Clinical algorithm of diagnosis and treatment of bone metastasis guideline.

Clinical algorithm of diagnosis and treatment of bone metastasis guideline. Clinical algorithm of diagnosis and treatment of bone metastasis guideline.
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
Waterfall plots of the best per cent change from baseline in sum of longest diameters (SLD) for target lesions. Waterfall plots of the best per cent change.

Waterfall plots of the best per cent change from baseline in sum of longest diameters (SLD) for target lesions. Waterfall plots of the best per cent change.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

Similar presentations

Ads by Google